Ignite Creation Date:
2024-05-06 @ 12:46 PM
Last Modification Date:
2024-10-26 @ 1:04 PM
Study NCT ID:
NCT03844932
Status:
TERMINATED
Last Update Posted:
2021-05-07
First Post:
2019-01-31
Brief Title:
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor:
Sublimity Therapeutics Holdco Limited
Organization:
Sublimity Therapeutics Holdco Limited
Study Overview
Official Title:
A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The Sublimity Board of Directors carefully evaluated the IA data the 96 treatment remission difference for 75mg BID vs placebo due to an increase in placebo response rate was determined not sufficient to continue to fund the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study CYC-202 is a multicenter randomized double-blind placebo-controlled parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score comprised of rectal bleeding stool frequency and endoscopy sub-scores score range 0-9
Detailed Description:
The study consists of a Screening period Treatment period and Follow-up The Screening period is comprised of two separate in-clinic visits SV1 and SV2 At the initial Screening visit SV1 subjects will be required to provide written informed consent to participate in the study and will then be assessed for eligibility Electronic diaries will be provided to subjects at this visit to use for the duration of the study in order to record information relating to their UC disease Subjects will return to the clinic for their Screening endoscopic assessment SV2 Ulcerative colitis disease activity for eligibility will be assessed using the 3-Component Adapted Mayo Score Upon successful completion of the Screening period subjects will return to the clinic for their Baseline visit
During the Treatment period subjects will be evaluated in the clinic at Baseline Day 1 Week 2 Week 4 Week 8 and Week 12 End of Treatment Period At Week 6 and Week 10 subjects will be contacted by telephone to assess Adverse Events AEs concomitant medication usage and study drug regimen adherence
Subjects who complete the 12-week Treatment period will attend the Week 16 End of Study EOS visit Subjects who discontinue study drug and withdraw or are withdrawn from the study before the Week 12 visit will be requested to return to the clinic as soon as possible to complete an Early Termination ET visit
During the Treatment period subjects will be evaluated in the clinic at Baseline Day 1 Week 2 Week 4 Week 8 and Week 12 End of Treatment Period At Week 6 and Week 10 subjects will be contacted by telephone to assess Adverse Events AEs concomitant medication usage and study drug regimen adherence
Subjects who complete the 12-week Treatment period will attend the Week 16 End of Study EOS visit Subjects who discontinue study drug and withdraw or are withdrawn from the study before the Week 12 visit will be requested to return to the clinic as soon as possible to complete an Early Termination ET visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None